Oncternal Therapeutics, Inc. (ONCT)
NASDAQ: ONCT · IEX Real-Time Price · USD
8.29
+0.08 (0.97%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Oncternal Therapeutics Revenue
In the year 2023, Oncternal Therapeutics had annual revenue of $785.00K, a decrease of -47.32%. Revenue in the quarter ending December 31, 2023 was $297.00K with 73.68% year-over-year growth.
Revenue (ttm)
$785.00K
Revenue Growth
-47.32%
P/S Ratio
31.26
Revenue / Employee
$29,074
Employees
27
Market Cap
24.54M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 785.00K | -705.00K | -47.32% |
Dec 31, 2022 | 1.49M | -2.83M | -65.47% |
Dec 31, 2021 | 4.32M | 940.00K | 27.85% |
Dec 31, 2020 | 3.38M | 950.00K | 39.18% |
Dec 31, 2019 | 2.43M | -96.00K | -3.81% |
Dec 31, 2018 | 2.52M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 8.07M | -48.72M | -85.80% |
Dec 31, 2010 | 56.79M | 42.06M | 285.51% |
Dec 31, 2009 | 14.73M | 1.20M | 8.89% |
Dec 31, 2008 | 13.53M | 6.40M | 89.84% |
Dec 31, 2007 | 7.13M | -379.00K | -5.05% |
Dec 31, 2006 | 7.51M | 3.72M | 98.44% |
Dec 31, 2005 | 3.78M | 1.92M | 102.57% |
Dec 31, 2004 | 1.87M | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Dec 31, 2000 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 52.55M |
Cumberland Pharmaceuticals | 39.55M |
Nephros | 14.24M |
Addex Therapeutics | 1.96M |
Sol-Gel Technologies | 1.55M |
Lipocine | -2.85M |
ONCT News
- 9 days ago - Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 6 weeks ago - Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - GlobeNewsWire
- 7 weeks ago - Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 4 months ago - Oncternal Therapeutics Announces Reverse Stock Split - GlobeNewsWire